[144] Nektar Therapeutics SEC Filing
Nektar Therapeutics (NKTR) filing reports a proposed sale of 5,166 common shares through Fidelity Brokerage Services with an aggregate market value of $174,119.16, to be sold approximately on 09/04/2025 on NASDAQ. The filing details that these shares were acquired via restricted stock vesting between 11/15/2017 and 05/15/2019, totaling specified lots (190; 1,346; 1,073; 1,072; 1,011; 474). It also discloses recent sales by the same person: 1,573 shares on 08/19/2025 for $41,826.23 and 1,500 shares on 09/02/2025 for $45,243.50. The signer represents no undisclosed material adverse information.
Nektar Therapeutics (NKTR) ha depositato una comunicazione per la vendita proposta di 5.166 azioni ordinarie tramite Fidelity Brokerage Services, per un valore di mercato complessivo di $174.119,16, con realizzo previsto indicativamente il 04/09/2025 sul NASDAQ. La comunicazione precisa che le azioni sono state acquisite mediante l'acquisizione di azioni soggette a restrizioni in vesting tra il 15/11/2017 e il 15/05/2019, suddivise nei lotti indicati (190; 1.346; 1.073; 1.072; 1.011; 474). Vengono inoltre dichiarate vendite recenti da parte della medesima persona: 1.573 azioni il 19/08/2025 per $41.826,23 e 1.500 azioni il 02/09/2025 per $45.243,50. Il sottoscrittore afferma di non essere in possesso di informazioni materiali sfavorevoli non divulgate.
Nektar Therapeutics (NKTR) present贸 un informe sobre la venta propuesta de 5.166 acciones ordinarias a trav茅s de Fidelity Brokerage Services, con un valor de mercado total de $174.119,16, que se prev茅 vender aproximadamente el 04/09/2025 en NASDAQ. El informe indica que estas acciones fueron adquiridas por la consolidaci贸n de acciones restringidas entre el 15/11/2017 y el 15/05/2019, en los lotes especificados (190; 1.346; 1.073; 1.072; 1.011; 474). Tambi茅n revela ventas recientes por la misma persona: 1.573 acciones el 19/08/2025 por $41.826,23 y 1.500 acciones el 02/09/2025 por $45.243,50. El firmante declara no poseer informaci贸n material adversa no divulgada.
Nektar Therapeutics (NKTR)臧� Fidelity Brokerage Services毳� 韱淀暣 齑� 鞁滌灔 臧�旃� $174,119.16鞚� 5,166 氤错喌欤� 毵り皝鞚� 鞝滌晥頃橂姅 鞁犼碃靹滊ゼ 鞝滌稖頄堨溂氅�, 頃措嫻 欤检嫕鞚� NASDAQ鞐愳劀 鞎� 2025-09-04鞐� 毵る弰霅� 鞓堨爼鞛呺媹雼�. 鞁犼碃靹滌棎電� 鞚� 欤检嫕霌れ澊 2017-11-15攵赌韯� 2019-05-15 靷澊 鞝滍暅欤� 氤挫湢鞚� 頃挫牅(氩犾姢韺�)毳� 韱淀暣 旆摑霅橃棃鞙茧┌, 歆�鞝曤悳 搿滍姼(190; 1,346; 1,073; 1,072; 1,011; 474)搿� 甑劚霅橃柎 鞛堧嫟瓿� 氇呾嫓霅橃柎 鞛堨姷雼堧嫟. 霃欖澕 鞚鸽鞚� 斓滉芳 毵り皝霃� 瓿店皽霅橃柎 鞛堧姅雿�, 2025-08-19鞐� 1,573欤茧ゼ $41,826.23鞐�, 2025-09-02鞐� 1,500欤茧ゼ $45,243.50鞐� 毵り皝頄堨姷雼堧嫟. 靹滊獏鞚胳潃 瓿店皽霅橃 鞎婌潃 欷戨寑頃� 攵堧Μ頃� 鞝曤炒臧� 鞐嗢潓鞚� 歆勳垹頃╇媹雼�.
Nektar Therapeutics (NKTR) a d茅pos茅 un avis concernant la vente propos茅e de 5 166 actions ordinaires via Fidelity Brokerage Services, pour une valeur de march茅 totale de $174 119,16, pr茅vue approximativement le 04/09/2025 sur le NASDAQ. L'avis indique que ces actions ont 茅t茅 acquises lors de la lev茅e de restrictions li茅es au vesting entre le 15/11/2017 et le 15/05/2019, r茅parties selon les lots indiqu茅s (190 ; 1 346 ; 1 073 ; 1 072 ; 1 011 ; 474). Sont 茅galement divulgu茅es des ventes r茅centes par la m锚me personne : 1 573 actions le 19/08/2025 pour $41 826,23 et 1 500 actions le 02/09/2025 pour $45 243,50. Le signataire d茅clare ne pas d茅tenir d'informations importantes d茅favorables non divulgu茅es.
Nektar Therapeutics (NKTR) hat eine Meldung 眉ber den geplanten Verkauf von 5.166 Stammaktien 眉ber Fidelity Brokerage Services eingereicht, mit einem Gesamtmarktwert von $174.119,16, der voraussichtlich am 04.09.2025 an der NASDAQ ver盲u脽ert werden soll. Die Meldung besagt, dass diese Aktien im Rahmen der Vesting-Freigabe eingeschr盲nkter Aktien zwischen dem 15.11.2017 und dem 15.05.2019 erworben wurden, aufgeteilt in die angegebenen Losgr枚脽en (190; 1.346; 1.073; 1.072; 1.011; 474). Ebenfalls offengelegt werden j眉ngste Verk盲ufe derselben Person: 1.573 Aktien am 19.08.2025 蹿眉谤 $41.826,23 und 1.500 Aktien am 02.09.2025 蹿眉谤 $45.243,50. Der Unterzeichner erkl盲rt, keine nicht offengelegten wesentlichen nachteiligen Informationen zu besitzen.
- Full disclosure of acquisition history by lot with dates and nature of acquisition (restricted stock vesting).
- Broker and planned sale details provided, including exchange (NASDAQ) and aggregate market value ($174,119.16).
- Insider has recently sold shares (1,573 on 08/19/2025 and 1,500 on 09/02/2025), which may be relevant to investors evaluating insider activity.
Insights
TL;DR Proposed sale is modest in size and follows recent smaller dispositions by the same holder.
The filing notifies a planned sale of 5,166 common shares valued at $174,119.16 to be executed on NASDAQ via Fidelity. Acquisition dates show these shares originated from multiple restricted stock vesting events between 2017 and 2019, indicating the shares are from compensation awards rather than recent open-market purchases. The filer previously sold 1,573 and 1,500 shares in August and September 2025, generating gross proceeds of $41,826.23 and $45,243.50 respectively. From a market-impact perspective, the disclosed quantities are small relative to the total outstanding shares reported at 19,018,573, implying limited dilution or liquidity impact.
TL;DR Disclosure is routine Rule 144 notice tied to vested compensation; no new governance issues disclosed.
The document supplies required Rule 144 details: broker identity, lot-by-lot acquisition via restricted stock vesting, nature of payment as compensation, and recent sales history. The representation about lacking undisclosed material adverse information is standard. There is no indication in the filing of insider trading plan dates, instructions under Rule 10b5-1, or any disclaimers beyond the statutory attestation. Governance implications are procedural; the filing does not reveal departures, policy changes, or material corporate events.
Nektar Therapeutics (NKTR) ha depositato una comunicazione per la vendita proposta di 5.166 azioni ordinarie tramite Fidelity Brokerage Services, per un valore di mercato complessivo di $174.119,16, con realizzo previsto indicativamente il 04/09/2025 sul NASDAQ. La comunicazione precisa che le azioni sono state acquisite mediante l'acquisizione di azioni soggette a restrizioni in vesting tra il 15/11/2017 e il 15/05/2019, suddivise nei lotti indicati (190; 1.346; 1.073; 1.072; 1.011; 474). Vengono inoltre dichiarate vendite recenti da parte della medesima persona: 1.573 azioni il 19/08/2025 per $41.826,23 e 1.500 azioni il 02/09/2025 per $45.243,50. Il sottoscrittore afferma di non essere in possesso di informazioni materiali sfavorevoli non divulgate.
Nektar Therapeutics (NKTR) present贸 un informe sobre la venta propuesta de 5.166 acciones ordinarias a trav茅s de Fidelity Brokerage Services, con un valor de mercado total de $174.119,16, que se prev茅 vender aproximadamente el 04/09/2025 en NASDAQ. El informe indica que estas acciones fueron adquiridas por la consolidaci贸n de acciones restringidas entre el 15/11/2017 y el 15/05/2019, en los lotes especificados (190; 1.346; 1.073; 1.072; 1.011; 474). Tambi茅n revela ventas recientes por la misma persona: 1.573 acciones el 19/08/2025 por $41.826,23 y 1.500 acciones el 02/09/2025 por $45.243,50. El firmante declara no poseer informaci贸n material adversa no divulgada.
Nektar Therapeutics (NKTR)臧� Fidelity Brokerage Services毳� 韱淀暣 齑� 鞁滌灔 臧�旃� $174,119.16鞚� 5,166 氤错喌欤� 毵り皝鞚� 鞝滌晥頃橂姅 鞁犼碃靹滊ゼ 鞝滌稖頄堨溂氅�, 頃措嫻 欤检嫕鞚� NASDAQ鞐愳劀 鞎� 2025-09-04鞐� 毵る弰霅� 鞓堨爼鞛呺媹雼�. 鞁犼碃靹滌棎電� 鞚� 欤检嫕霌れ澊 2017-11-15攵赌韯� 2019-05-15 靷澊 鞝滍暅欤� 氤挫湢鞚� 頃挫牅(氩犾姢韺�)毳� 韱淀暣 旆摑霅橃棃鞙茧┌, 歆�鞝曤悳 搿滍姼(190; 1,346; 1,073; 1,072; 1,011; 474)搿� 甑劚霅橃柎 鞛堧嫟瓿� 氇呾嫓霅橃柎 鞛堨姷雼堧嫟. 霃欖澕 鞚鸽鞚� 斓滉芳 毵り皝霃� 瓿店皽霅橃柎 鞛堧姅雿�, 2025-08-19鞐� 1,573欤茧ゼ $41,826.23鞐�, 2025-09-02鞐� 1,500欤茧ゼ $45,243.50鞐� 毵り皝頄堨姷雼堧嫟. 靹滊獏鞚胳潃 瓿店皽霅橃 鞎婌潃 欷戨寑頃� 攵堧Μ頃� 鞝曤炒臧� 鞐嗢潓鞚� 歆勳垹頃╇媹雼�.
Nektar Therapeutics (NKTR) a d茅pos茅 un avis concernant la vente propos茅e de 5 166 actions ordinaires via Fidelity Brokerage Services, pour une valeur de march茅 totale de $174 119,16, pr茅vue approximativement le 04/09/2025 sur le NASDAQ. L'avis indique que ces actions ont 茅t茅 acquises lors de la lev茅e de restrictions li茅es au vesting entre le 15/11/2017 et le 15/05/2019, r茅parties selon les lots indiqu茅s (190 ; 1 346 ; 1 073 ; 1 072 ; 1 011 ; 474). Sont 茅galement divulgu茅es des ventes r茅centes par la m锚me personne : 1 573 actions le 19/08/2025 pour $41 826,23 et 1 500 actions le 02/09/2025 pour $45 243,50. Le signataire d茅clare ne pas d茅tenir d'informations importantes d茅favorables non divulgu茅es.
Nektar Therapeutics (NKTR) hat eine Meldung 眉ber den geplanten Verkauf von 5.166 Stammaktien 眉ber Fidelity Brokerage Services eingereicht, mit einem Gesamtmarktwert von $174.119,16, der voraussichtlich am 04.09.2025 an der NASDAQ ver盲u脽ert werden soll. Die Meldung besagt, dass diese Aktien im Rahmen der Vesting-Freigabe eingeschr盲nkter Aktien zwischen dem 15.11.2017 und dem 15.05.2019 erworben wurden, aufgeteilt in die angegebenen Losgr枚脽en (190; 1.346; 1.073; 1.072; 1.011; 474). Ebenfalls offengelegt werden j眉ngste Verk盲ufe derselben Person: 1.573 Aktien am 19.08.2025 蹿眉谤 $41.826,23 und 1.500 Aktien am 02.09.2025 蹿眉谤 $45.243,50. Der Unterzeichner erkl盲rt, keine nicht offengelegten wesentlichen nachteiligen Informationen zu besitzen.
FAQ
What is the size and value of the proposed sale in the NKTR Form 144?
When is the NKTR proposed sale scheduled and on which exchange?
How were the shares being sold acquired according to the filing?
Has the filer sold shares recently prior to this notice?
Does the filing state any undisclosed material information about Nektar Therapeutics?
